Daiwa Securities Group
VYNE icon

Daiwa Securities Group’s VYNE Therapeutics VYNE Stock Holding History

Daiwa Securities Group’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4
Closed – – 1450
2021
Q3 		$0 Hold
4
– – ﹤0.01% 1344
2021
Q2 		$0 Hold
4
– – ﹤0.01% 1292
2021
Q1 		$1K Hold
4
– – ﹤0.01% 1231
2020
Q4 		$0 Buy
+4
New +$503 ﹤0.01% 1301

Other funds holding VYNE

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Daiwa Securities Group's VYNE Position: Q4 2021 in Review

Daiwa Securities Group sold out of VYNE Therapeutics (VYNE) in Q4 2021, closing a stake of 4 shares.

Daiwa Securities Group first reported a position in VYNE in Q4 2020 and held it in 4 quarters. The position peaked at $1K in Q1 2021. 54 funds tracked by Wall St. Rank hold VYNE as of Q4 2021.

  • Daiwa Securities Group reported no remaining VYNE Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Daiwa Securities Group sold 4 VYNE Therapeutics shares in Q4 2021.
  • Daiwa Securities Group first reported a position in VYNE Therapeutics in Q4 2020 and held it in 4 quarters.
  • Daiwa Securities Group's VYNE Therapeutics position peaked at $1K in Q1 2021.
  • 54 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q4 2021.

Based on Daiwa Securities Group's 13F filing for Q4 2021, filed 3 Feb 2022.